• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by National Research Corporation

    3/27/26 4:35:08 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $NRC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)


    National Research Corporation

    (Name of Issuer)


    Common Stock, $.001 par value

    (Title of Class of Securities)




    637372202

    (CUSIP Number)
    Patrick E. Beans, Amandla, LLC
    709 Pier 2,
    Lincoln, NE, 68528
    402-440-2768


    Joel I. Greenberg, Esq.
    Arnold & Porter Kaye Scholer LLP, 250 West 55th Street
    New York, NY, 10019-9710
    212-836-8000


    Mark A. Scudder, Esq.
    Scudder Law Firm, P.C., L.L.O., 411 South 13th Street, Suite 200
    Lincoln, NE, 68508
    402-435-3223

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/26/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    schemaVersion:


    SCHEDULE 13D

    CUSIP Number(s):
    637372202


    1 Name of reporting person

    Common Property Trust
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    8,609,601.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    8,609,601.00
    11Aggregate amount beneficially owned by each reporting person

    8,609,601.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    37.9 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The percentage indicated in Row (13) is based upon 22,746,397 shares of Common Stock outstanding as of February 28, 2026, as reported in the Issuer's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 5, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    637372202


    1 Name of reporting person

    Common Property Trust LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    3,854,284.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    3,854,284.00
    11Aggregate amount beneficially owned by each reporting person

    3,854,284.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    16.9 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The percentage indicated in Row (13) is based upon 22,746,397 shares of Common Stock outstanding as of February 28, 2026, as reported in the Issuer's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 5, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    637372202


    1 Name of reporting person

    Amandla, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,755,317.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,755,317.00
    11Aggregate amount beneficially owned by each reporting person

    4,755,317.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    20.9 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The percentage indicated in Row (13) is based upon 22,746,397 shares of Common Stock outstanding as of February 28, 2026, as reported in the Issuer's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 5, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    637372202


    1 Name of reporting person

    Beans Patrick E.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    SC, PF, OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    35,003.00
    8Shared Voting Power

    10,540,631.00
    9Sole Dispositive Power

    35,003.00
    10Shared Dispositive Power

    10,540,631.00
    11Aggregate amount beneficially owned by each reporting person

    10,575,634.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    46.5 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    The percentage indicated in Row (13) is based upon 22,746,397 shares of Common Stock outstanding as of February 28, 2026, as reported in the Issuer's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 5, 2026.


    SCHEDULE 13D

    CUSIP Number(s):
    637372202


    1 Name of reporting person

    Hays Michael D.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    SC, OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    45,171.00
    8Shared Voting Power

    802,128.00
    9Sole Dispositive Power

    45,171.00
    10Shared Dispositive Power

    802,128.00
    11Aggregate amount beneficially owned by each reporting person

    847,299.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox checked
    13Percent of class represented by amount in Row (11)

    3.7 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    See footnote (4) to Item 5 herein for a detailed description of shares disclosed in this report with respect to which Mr. Hays disclaims beneficial ownership. The percentage indicated in Row (13) is based upon 22,746,397 shares of Common Stock outstanding as of February 28, 2026, as reported in the Issuer's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 5, 2026.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $.001 par value
    (b)Name of Issuer:

    National Research Corporation
    (c)Address of Issuer's Principal Executive Offices:

    1245 Q Street, Lincoln, NEBRASKA , 68508.
    Item 1 Comment:
    This Amendment No. 3 to Schedule 13D ("Amendment No. 3"), which relates to shares of the Common Stock, par value $.001 per share (the "Common Stock"), of National Research Corporation, a Delaware corporation (the "Issuer") is being filed by: (i) Common Property Trust ("CPT"); (ii) Common Property Trust LLC, a Delaware limited liability company ("CPT LLC"), (iii) Amandla LLC, a Delaware limited liability company ("Amandla LLC"); (iv) Patrick E. Beans, ("PB"), and (v) Michael D. Hays, the founder and Chairman of the Board of the Issuer ("MH", and collectively with CPT, CPT LLC, Amandla LLC and PB, the "Reporting Persons"). This Amendment No. 3 amends the Schedule 13D initially filed on March 22, 2021, as amended by Amendment No. 1 thereto filed on March 5, 2024 by: (x) Thomas Richardson, as the trustee of CPT and Manager of CPT LLC ("TR"), (y) CPT, and (z) CPT LLC, and Amendment No. 2 thereto filed on April 10, 2025 ("Amendment No. 2") by the Reporting Persons and TR (collectively, the "CPT 13D"). This Amendment No. 3 is filed to reflect the relinquishment of MH's right to reacquire at any time, by substituting other property having equivalent value therefor, an aggregate of 582,688 shares of Common Stock held by certain irrevocable trusts established by MH for the benefit of various family members. Neither the filing of this Amendment No. 3 nor any of its contents shall be deemed to constitute: (i) an admission that MH is the beneficial owner of the Common Stock beneficially owned by his spouse, CPT, CPT LLC, or Amandla LLC, or any of the Excluded Shares (as defined herein), for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), Section 16 of the Exchange Act, or for any other purpose, and MH expressly disclaims beneficial ownership of such shares and (ii) an assertion or presumption that any of the persons on whose behalf this Amendment No. 3 is filed constitute a "group." This Amendment No. 3 amends the CPT 13D (as previously amended) as set forth below.
    Item 2.Identity and Background
    (a)
    This Schedule 13D is being filed jointly by: (i) CPT; (ii) CPT LLC; (iii) Amandla LLC; (iv) PB; and (v) MH. Each of the foregoing is referred to as a "Reporting Person" and, collectively, as the "Reporting Persons." Each of the Reporting Persons is a party to that certain Joint Filing Agreement attached as Exhibit 99.1 to Amendment No. 2.
    (b)
    The principal business address of CPT is 20 Montchanin Road, Suite 100, Greenville, DE 19807. The principal business address of Amandla LLC, CPT LLC and PB is 709 Pier 2, Lincoln, NE 68528. The principal business address of MH is c/o National Research Corp., 1245 "Q" Street, Lincoln, Nebraska 68508.
    (c)
    The principal occupation of PB is financial advisor; the principal occupation of MH is the Chairman of the Issuer. CPT, CPT LLC and Amandla LLC were formed to implement MH's estate plans for the benefit of various family members. Addresses are set forth in paragraph (b) above.
    (d)
    None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    None of the Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.
    (f)
    CPT is governed by the laws of the state of Delaware. Each of CPT LLC and Amanda LLC is a Delaware limited liability company. PB and MH are each citizens of the United States.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 is hereby amended to add the phrase "using personal funds" to the end of the last sentence thereof.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5 is hereby amended and restated to read in its entirety as follows: (a) Set forth below is the aggregate number and percentage of outstanding shares of Common Stock owned beneficially by each Reporting Person based on 22,746,397 shares of Common Stock outstanding as of February 28, 2026 as reported in the Issuer's Annual Report on Form 10-K, as filed with the Securities and Exchange Commission on March 5, 2026: Sole Power Shared Power Sole Power Shared Power Amount to Vote to Vote to Dispose or to Dispose or Reporting Beneficially Percent or Direct or Direct Direct the Direct the Person Owned of Class the Vote the Vote Disposition Disposition CPT LLC (1) 3,854,284 16.9% 0 3,854,284 0 3,854,284 Amandla LLC (2) 4,755,317 20.9% 0 4,755,317 0 4,755,317 CPT (3) 8,609,601 37.9% 0 8,609,601 0 8,609,601 MH (4) 847,299 3.7% 45,171 802,128 45,171 802,128 PB (5) 10,575,634 46.5% 35,003 10,540,631 35,003 10,540,631 (1) CPT LLC is the direct holder of 3,854,284 shares of Common Stock (the "CPT LLC Shares"). (2) Amandla LLC is the direct holder of 4,755,317 shares of Common Stock (the "Amandla Shares"). (3) CPT, as the 100% owner of each of CPT LLC and Amandla LLC, shares beneficial ownership of the CPT LLC Shares with CPT LLC and shares beneficial ownership of the Amandla Shares with Amandla LLC. (4) Includes: (i) 20,154 shares of Common Stock held directly by MH (over which he has sole voting and dispositive power); (ii) 25,017 shares of Common Stock under currently exercisable stock options (over which he has sole voting and dispositive power); (iii) 76,095 shares of Common Stock held by MH's wife (MH disclaims beneficial ownership of the shares held by his wife); and (iv) 726,033 shares of Common Stock (the "Irrevocable Trust Shares") held directly by various irrevocable trusts (the "Irrevocable Trusts") created by MH for the benefit of various family members, that MH has the right to reacquire at any time by substituting other property having equivalent value therefor (the "Reacquisition Right"), such that MH shares beneficial ownership of the Irrevocable Trust Shares with the Irrevocable Trusts. Excludes (collectively, the "Excluded Shares"): (i) the CPT LLC Shares; (ii) the Amandla Shares; (iii) 47,110 shares of Common Stock (the "1999 Trust Shares") held directly by a trust created by MH for the benefit of various family members (the "1999 Trust"); and (iv) an aggregate of 142,597 shares of Common Stock (the "Family Trust Shares") held directly by two irrevocable trusts created by MH for the benefit of various family members (the "Family Trusts"). MH has the power to replace the manager of Amandla LLC and CPT LLC (currently PB), who has direct voting and dispositive power with respect to shares held by those entities, at any time, so long as the replacement in each case is not MH himself or anyone related or subordinate to MH within the meaning of Section 672(c) of the Internal Revenue Code of 1986, as amended (the "Code"). As a result, MH may be deemed to be the beneficial owner of the CPT LLC Shares and the Amandla Shares, however, MH disclaims beneficial ownership of all such shares. MH also has the power to replace the trustee of the 1999 Trust (currently PB), who has direct voting and dispositive power with respect to the 1999 Trust Shares, at any time, so long as the replacement is not MH himself or anyone related or subordinate to MH within the meaning of Section 672(c) of the Code. As a result, MH may be deemed to be the beneficial owner of the 1999 Trust Shares, however, MH disclaims beneficial ownership of the 1999 Trust Shares. In addition, MH has the power to replace the Protector of the Family Trusts, who can in turn replace the Special Holdings Direction Advisor of the Family Trusts at any time (currently PB), who has direct voting and dispositive power with respect to the Family Trust Shares, so long as the replacement in each case is not MH himself or anyone related or subordinate to MH within the meaning of Section 672(c) of the Code. As a result, MH may be deemed to be the beneficial owner of the Family Trust Shares, however, MH disclaims beneficial ownership of the Family Trust Shares. Neither the filing of this Amendment No. 3 nor any of its contents shall be deemed to constitute an admission that MH is the beneficial owner of any shares of Common Stock held by his spouse or any Excluded Shares for purposes of Section 13(d) of the Exchange Act, Section 16 of the Exchange Act, or for any other purpose. (5) Includes: (i) 35,003 shares of Common Stock held by PB directly; (ii) the CPT LLC Shares and the Amandla Shares (PB is the manager of Amandla LLC and CPT LLC); (iii) the Irrevocable Trust Shares (PB is the Special Holdings Direction Advisor and Protector of the Irrevocable Trusts); (iv) the Family Trust Shares (PB is the Special Holdings Direction Advisor and Protector of the Family Trusts); (v) the 1999 Trust Shares (PB is the trustee of the 1999 Trust); (vi) an aggregate of 423,561 shares of Common Stock (the "Additional Shares") held directly by various trusts created by MH (the "Additional Shares Trusts") for the benefit of various family members (PB is the Special Holdings Direction Advisor and Protector of the Additional Shares Trusts, with direct voting and dispositive power over the Additional Shares); (vii) an aggregate of 312,629 shares of Common Stock (the "Burr Oak Shares") held directly by various limited liability companies (the "Burr Oak LLCs") that are 100% owned by certain of the Irrevocable Trusts, the Family Trusts and an Additional Share Trust (the "Burr Oak Irrevocable Trusts") (PB is the Special Manager of the Burr Oak LLCs); and (viii) 279,100 shares of Common Stock (the "Foundation Shares") held by a charitable foundation formed by MH (PB is one of two members of the Special Holdings Direction Advisor Committee for such foundation). As a result, PB shares beneficial ownership over: (i) the CPT LLC Shares with CPT and CPT LLC; (ii) the Amandla Shares with CPT and Amandla LLC; (iii) the Irrevocable Trust Shares with the Irrevocable Trusts and MH; (iv) the Family Trust Shares with the Family Trusts; (iv) the 1999 Trust Shares with the 1999 Trust; (v) the Additional Trust Shares with the Additional Trusts; (vi) the Burr Oak Shares with the Burr Oak LLCs and the Burr Oak Irrevocable Trusts; and (vi) the Foundation Shares with the other member of the Special Holdings Direction Advisor Committee for such foundation and such foundation (PB disclaims beneficial ownership of the Foundation Shares).
    (b)
    See paragraph (a) above.
    (c)
    Other than as described herein, there have been no transactions in the Common Stock by the Reporting Persons during the past 60 days.
    (d)
    Other than: (i) the Irrevocable Trusts, which hold the Irrevocable Trust Shares directly; (ii) the 1999 Trust, which holds the 1999 Trust Shares directly; (iii) the Family Trusts, which hold the Family Trust Shares directly; (iv) the Additional Share Trusts, which hold the Additional Shares directly; (v) the Burr Oak LLCs, which hold the Burr Oak Shares directly, and the Burr Oak Irrevocable Trusts, which own the Burr Oak LLCs; and (vi) the foundation that holds the Foundation Shares directly, no person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, Common Stock beneficially owned by any Reporting Person (and none of the individual interests of any of the entities described above relates to more than 5% of the Common Stock outstanding).
    (e)
    Excluding the Excluded Shares, as of March 23, 2026, MH ceased to be the beneficial owner of more than five percent of the Common Stock.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Item 6 is amended by adding the following after the last paragraph thereof: MH holds options to purchase: (i) 4,523 shares of Common Stock at an exercise price of $42.25 that vest on January 4, 2027; (ii) 4,909 shares of Common Stock at an exercise price of $38.93 that vest on January 4, 2028; (iii) 11,021 shares of Common Stock at an exercise price of $17.34 that vest on January 10, 2030; and (iv) 4,833 shares of Common Stock at an exercise price of $39.54 that vest upon the Issuer achieving a minimum total recurring contract value of $170 million as of December 31, 2026.
    Item 7.Material to be Filed as Exhibits.
     
    Item 7 of the CPT 13D is amended by adding the following exhibit thereto: 99.15 Form of Nonqualified Stock Option Agreement, incorporated by reference to Exhibit 10.14 to National Research Corporation's Annual Report on Form 10-K for the year ended December 31, 2006, filed on April 2, 2007 99.16 Form of Option Award Notice, incorporated by reference to Exhibit 10.2 to National Research Corporation's Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed on May 9, 2024

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Common Property Trust
     
    Signature:/s/ Thomas Richardson
    Name/Title:Thomas Richardson, as Trustee
    Date:03/27/2026
     
    Common Property Trust LLC
     
    Signature:/s/ Patrick E. Beans
    Name/Title:Patrick E. Beans, as Manager
    Date:03/27/2026
     
    Amandla, LLC
     
    Signature:/s/ Patrick E. Beans
    Name/Title:Patrick E. Beans, as Manager
    Date:03/27/2026
     
    Beans Patrick E.
     
    Signature:/s/ Patrick E. Beans
    Name/Title:Patrick E. Beans
    Date:03/27/2026
     
    Hays Michael D.
     
    Signature:/s/ Michael D. Hays
    Name/Title:Michael D. Hays
    Date:03/27/2026
    Get the next $NRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Rau Jason Russell was granted 60,000 shares (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    3/13/26 4:39:55 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP & Chief Financial Officer Harrison Shane R bought $98,162 worth of shares (8,000 units at $12.27) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/19/26 5:02:50 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Lockhart Stephen H

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/17/26 7:21:50 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Piedmont Names NRC Health as a Strategic Experience Partner to Support Mission-Driven Growth

    Piedmont, a Georgia-based healthcare system with nationally-ranked clinical programs, has named NRC Health, the leader in healthcare experience management, as its new strategic experience partner to support the organization's mission-driven growth and commitment to making a positive difference in every life it touches. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260319999984/en/Piedmont, a Georgia-based healthcare system with nationally-ranked clinical programs, has named NRC Health, the leader in healthcare experience management, as its new strategic experience partner to support the organization's mission-driven growth and

    3/19/26 8:01:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Board Authorization of $60 Million Share Repurchase Program

    National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced that its Board of Directors authorized a stock repurchase program of up to $60 million of the company's outstanding common stock through March 31, 2028. NRC Health may repurchase shares from time to time in the open market, through privately negotiated transactions and/or other means in compliance with the Securities Exchange Act of 1934 and the rules and regulations thereunder. Open market repurchases may be structured to occur in accordance with the requirements of Rule 10b-18 under the Exchange Act. The Company may also, from time to time, enter into Rul

    3/9/26 4:30:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Provides Business Update

    TRCV surpasses $152 million, increasing 6% from the end of 2025 and 13% year-over-year National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced that it has surpassed $152 million in Total Recurring Contract Value (TRCV) as of March 4, 2026, representing an all-time high in the metric for NRC Health. TRCV represents the amount of revenue projected to be recognized over the next 12 months from renewable contracts and is calculated consistent with the definition previously disclosed in the company's periodic reports filed with the Securities and Exchange Commission. "This TRCV milestone reflects the confidence o

    3/4/26 4:15:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by National Research Corporation

    SCHEDULE 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/27/26 4:35:08 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form S-8 filed by National Research Corporation

    S-8 - NATIONAL RESEARCH CORP (0000070487) (Filer)

    3/5/26 12:47:06 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-K filed by National Research Corporation

    10-K - NATIONAL RESEARCH CORP (0000070487) (Filer)

    3/5/26 9:57:16 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Harrison Shane R bought $98,162 worth of shares (8,000 units at $12.27) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    2/19/26 5:02:50 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Accounting Officer Freeman Jordan Nicole bought $10,000 worth of shares (771 units at $12.97) (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    8/4/25 4:40:44 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Large owner Beans Patrick E bought $33,974 worth of shares (2,500 units at $13.59), increasing direct ownership by 8% to 35,003 units (SEC Form 4)

    4 - NATIONAL RESEARCH CORP (0000070487) (Issuer)

    5/13/25 11:30:22 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Leadership Updates

    Live Leadership Updates

    View All

    NRC Health Appoints David Burik as Executive Vice President, Strategic Insights

    Seasoned healthcare strategy leader to advance The Governance Institute and Market Insights NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251120531393/en/NRC Health, the leader in healthcare experience management, today announced the appointment of David Burik as Executive Vice President, Strategic Insights, effective January 5, 2026. David joins NRC Health from Guidehouse, where he has served as partner and leader of the Center for Health Insigh

    11/20/25 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Shane Harrison as Chief Financial Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare experience, is pleased to announce the appointment of Shane Harrison as its incoming Executive Vice President and Chief Financial Officer, effective on or about September 25, 2025. Chief Financial Officer Shane Harrison is a seasoned finance leader with more than 25 years of experience spanning corporate finance, investor relations, and strategic transactions. He most recently served as Senior Vice President – Finance and Investor Relations at PowerSchool, a leading K-12 education SaaS provider, since 2022. Prior to that, he served as Senior Vice President – Corporate Develop

    8/28/25 8:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    National Research Corporation Appoints Trent Green as Chief Executive Officer

    National Research Corporation (NASDAQ:NRC), doing business as NRC Health, a publicly-traded leader in healthcare improvement, is pleased to announce the appointment of Trent Green as its incoming Chief Executive Officer, effective June 1, 2025. Green will succeed Mike Hays, the company's current CEO, who will transition to the role of Chairman, ensuring a smooth leadership transition while maintaining NRC Health's mission-driven and shareholder-focused approach. Green brings more than 25 years of healthcare leadership experience, most recently serving as CEO of One Medical, San Francisco, CA, and previously as Chief Operating Officer at Legacy Health, Portland, OR. His expertise in care de

    3/4/25 4:01:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Financials

    Live finance-specific insights

    View All

    NRC Health Announces Board Authorization of $60 Million Share Repurchase Program

    National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced that its Board of Directors authorized a stock repurchase program of up to $60 million of the company's outstanding common stock through March 31, 2028. NRC Health may repurchase shares from time to time in the open market, through privately negotiated transactions and/or other means in compliance with the Securities Exchange Act of 1934 and the rules and regulations thereunder. Open market repurchases may be structured to occur in accordance with the requirements of Rule 10b-18 under the Exchange Act. The Company may also, from time to time, enter into Rul

    3/9/26 4:30:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Provides Business Update

    TRCV surpasses $152 million, increasing 6% from the end of 2025 and 13% year-over-year National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced that it has surpassed $152 million in Total Recurring Contract Value (TRCV) as of March 4, 2026, representing an all-time high in the metric for NRC Health. TRCV represents the amount of revenue projected to be recognized over the next 12 months from renewable contracts and is calculated consistent with the definition previously disclosed in the company's periodic reports filed with the Securities and Exchange Commission. "This TRCV milestone reflects the confidence o

    3/4/26 4:15:00 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    NRC Health Announces Fourth Quarter 2025 Results

    Fourth quarter TRCV* increased 8% year-over-year to $144.1 million Cash flow from operations increased 13% year-over-year to $7.2 million National Research Corporation, dba NRC Health, (NASDAQ:NRC), a leader in healthcare experience improvement solutions, today announced results for the fourth quarter 2025. "Our fourth quarter results reflect the strong, disciplined execution happening across NRC Health and the deep trust our customers place in us," said Trent Green, CEO of NRC Health. "With TRCV reaching $144 million and momentum building across our portfolio, we finished the year with a strong foundation for continued execution. As healthcare leaders navigate unprecedented complexit

    2/3/26 9:00:00 AM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $NRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Research Corporation

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    11/13/24 4:05:19 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by National Research Corporation (Amendment)

    SC 13G/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/8/24 4:05:05 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D/A filed by National Research Corporation (Amendment)

    SC 13D/A - NATIONAL RESEARCH CORP (0000070487) (Subject)

    3/5/24 4:31:31 PM ET
    $NRC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care